Patent specialists are sounding the alarm about the intellectual property terms in the recently finalized India-UK Trade Pact, which they claim will restrict India's ability to ensure affordable access to essential medicines...
India's drug and pharmaceutical exports have increased by 92%, from Rs 1,28,028 crore in FY2018-19 to Rs 2,45,962 crore in FY2024-25, thanks to a number of initiatives the Center is implementing to realize the vision of Aatmanirbhar Bharat
The Delhi High Court has declined to issue directions to Zydus Lifesciences to disclose the manufacturing process of its breast cancer drug Sigrima, following a plea by Swiss multinational F. Hoffmann-La Roche.
Pfizer has entered a worldwide license deal, with the exception of China, with Chinese company 3SBio to obtain exclusive rights to develop, make, and sell 3SBio's investigational bispecific antibody, SSGJ-707.
Union Health Minister J P Nadda informed the Lok Sabha on Friday that an ICMR study had shown that the Covid vaccine did not raise the risk of sudden, unexplained deaths among young adults in India
A potential stem cell treatment for chronic liver failure was successfully evaluated by a startup based at the University of Hyderabad (UoH). The company claims that the treatment, known as Tulsi-28X, is the first in the world to employ a unique
Approval has been received by Lupin Limited from the United States Food and Drug Administration for its Abbreviated New Drug Applications for Liraglutide Injection Single-Patient-Use Prefilled Pens and Glucagon for Injection vials...
Under the Production Linked Incentive (PLI) Scheme aimed at increasing domestic manufacturing of critical Key Starting Materials (KSMs), Drug Intermediates (DIs), and Active Pharmaceutical Ingredients (APIs)
The historic India-UK Free Trade Agreement (FTA) signed on Thursday will radically boost bilateral trade, particularly in the pharma and medical devices sector, said industry experts.
.jpeg "Zydus Receives Tentative Approval from USFDA for Ibrutinib Tablets")
Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received tentative approval from the United States Food and Drug Administration (USFDA) for Ibrutinib tablets 140 mg, 280 mg, and 420 mg (USRLD
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")
